Abstracts Archive - Page 1459 of 2425 - ACR Meeting Abstracts

Abstract Number: 619 • 2016 ACR/ARHP Annual Meeting
Concomitant Treatment Use during Treatment with Golimumab in Patients with Rheumatoid Arthritis
Philip Baer¹, Mary Bell², Boulos Haraoui³, Louis Bessette⁴, John Kelsall⁵, Maqbool Sheriff⁶, Emmanouil Rampakakis⁷, Eliofotisti Psaradellis⁸, Francois Nantel⁹, Allen J Lehman¹⁰, Brendan Osborne¹¹, Cathy Tkaczyk¹¹ and Karina Maslova¹⁰, ¹Independent Rheumatology Practice, Scarborough, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³University of Montreal, Montreal, QC, Canada, ⁴Rheumatology, CHUL de Quebec, Quebec, QC, Canada, ⁵Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁶Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁷JSS Medical Research, St-Laurent, QC, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Previous studies have shown that, when sustained good clinical response has been achieved with a biologic therapy, traditional disease-modifying anti-rheumatic drugs (DMARDs) and other…
Abstract Number: 620 • 2016 ACR/ARHP Annual Meeting
Clinical Activity, Ultrasound Assessment and Drug Monitoring in Rheumatoid Arthritis Patients Receiving Anti-TNF-α Therapy with Extended Interval of Administration
José Miguel Senabre-Gallego¹, José Rosas¹, Francisca Llinares-Tello², Mariana Marco-Mingot², Ana Pons¹, Xavier Barber³, Gregorio Santos-Soler¹, Esteban Salas-Heredia¹, Catalina Cano¹, Marisa Lorente⁴, Marina Sanchís³, Juan Molina², Mario García-Carrasco⁵ and AIRE-MB, ¹Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ²Laboratory, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ³CIO, Universidad Miguel Hernández, Elche, Spain, ⁴Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, ⁵Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR Instituto Mexicano del Seguro Social, Puebla, Mexico
Background/Purpose: To assess clinical activity, ultrasound synovitis and drug levels in rheumatoid arthritis (RA) patients receiving anti-TNFα therapy with extended interval of administration (EIA). Methods:…
Abstract Number: 621 • 2016 ACR/ARHP Annual Meeting
Effectiveness and Safety of CT- P13 (Biosimilar Reference Infliximab) in a Real-Life Setting in 151 Patients with Rheumatoid Arthritis and Ankylosing Spondylitis: A Mid-Term Interim Analysis
Catalin Codreanu¹, Klara Sirova², Katerina Jarosova³ and Anastas Batalov⁴, ¹Rheumatology, 'Dr. Ion Stoia' Clinical Center of Rheumatic Diseases, Bucharest, Romania, ²Revmatologie, Revmatologie MU Dr. Klara Sirova, sro, Ostrava, Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic, ⁴Rheumatology, Medical University of Plovdiv, UMHAT Kaspela, Plovdiv, Bulgaria
Background/Purpose: Over the past decade, the use of biologics has significantly changed the management of rheumatoid arthritis (RA) and ankylosing spondylitis (AS). However, the high…
Abstract Number: 622 • 2016 ACR/ARHP Annual Meeting
Efficacy after Transition to SB5 from Reference Adalimumab (Humira®) Vs. Continuation of SB5 or Reference Adalimumab By Antibodies Developed after Transition from a SB5 Phase III Study
Mark C. Genovese¹, Michael Weinblatt², Edward C. Keystone³, Asta Baranauskaite⁴, Soo Yeon Cheong⁵ and Jeehoon Ghil⁵, ¹Stanford University Medical Center, Palo Alto, CA, ²Brigham and Women’s Hospital, Boston, MA, ³Mount Sinai Hospital, Toronto, ON, Canada, ⁴Lithuanian University of Health Sciences, Kaunas, Lithuania, ⁵Samsung Bioepis Co., Ltd., Incheon, South Korea
Background/Purpose : SB5 has been developed as a biosimilar of the reference adalimumab (ADL). The 52-week efficacy and safety results were reported previously. 1 Here…
Abstract Number: 623 • 2016 ACR/ARHP Annual Meeting
WITHDRAWN
Abstract Number: 624 • 2016 ACR/ARHP Annual Meeting
Association Between Methotrexate Use and Effects of Treatment with a Second Biologic Agent in Rheumatoid Arthritis
Yoshikazu Ogawa¹, Nobunori Takahashi², Toshihisa Kojima³ and Naoki Ishiguro⁴, ¹orthopedic surgery, Sakashita Hospital, Nakatsugawa, Japan, ²Nagoya Univ. Grad. Schl. of Med., Nagoya, Japan, ³Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ⁴Nagoya University, Nagoya, Japan
Background/Purpose: In general, the concomitant use of methotrexate (MTX) and biologic disease-modifying antirheumatic drugs (bDMARDS) plays an important role in treating bio-naïve patients with rheumatoid…
Abstract Number: 625 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Intravenous Golimumab Plus Methotrexate in Patients 65 Years and Younger and Those Greater Than 65 Years of Age-a Post-Hoc Analysis
John Tesser¹, Shelly Kafka², Raphael J. DeHoratius³, Stephen Xu⁴, Kehzen L. Tang⁴, Elizabeth C. Hsia⁵ and Anthony Turkiewicz⁶, ¹Arizona Arthritis & Rheumatology Associates, Glendale, AZ, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Scientific Affairs, LLC/Sidney Kimmel School of Medicine, Thomas Jefferson University, Horsham/Philadelphia, PA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁶Rheumatology Associates, Birmingham, AL
Background/Purpose: There is a paucity of data on the use of anti-TNF therapy in patients >65 years. In this sub-analysis of GO-FURTHER, we compare the…
Abstract Number: 626 • 2016 ACR/ARHP Annual Meeting
Switching Biologic Therapy in a Population of Rheumatoid Arthritis Patients
Branca Souza¹, Juliana Valim², Fernanda Chaer³, Fernanda Guimarães⁴ and Verônica Lima⁵, ¹Reumatologia, Irmandade da Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, ²Rheumatology, Santa Casa de São Paulo, São Paulo, Brazil, ³Rheumatology, Irmandade da Santa Casa de São Paulo, São Paulo, Brazil, ⁴Rheumatology, Irmandade Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, ⁵Rheumatology, Irmandade Santa Casa de São Paulo, São Paulo, Brazil
Background/Purpose: Evaluate the reason of exchange of biologic therapy in patients with rheumatoid arthritis and describe the frequency of remission or low activity, according to…
Abstract Number: 627 • 2016 ACR/ARHP Annual Meeting
Clinical and Immunogenicity Outcomes after Switching Treatment from Innovator Infliximab to Biosimilar Infliximab in Rheumatic Diseases in Daily Clinical Practice
L Tweehuysen¹, B.J.F. van den Bemt², I.L. van Ingen³, A.J.L. de Jong⁴, W.H. van der Laan⁵, F.H.J. van den Hoogen⁵ and A.A. den Broeder⁵, ¹Sint Maartenskliniek Nijmegen, Nijmegen, Netherlands, ²Pharmacy, Sint Maartenskliniek Nijmegen, Nijmegen, Netherlands, ³Rheumatology, Radboudumc Nijmegen, Nijmegen, Netherlands, ⁴Department of Rheumatology, Rijnstate Arnhem, Arnhem, Netherlands, ⁵Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Biosimilar infliximab is registered in Europe for the same therapeutic indications as innovator infliximab. In 2015, four rheumatology departments in the Netherlands decided to…
Abstract Number: 628 • 2016 ACR/ARHP Annual Meeting
Analysis of Baseline Characteristics of Rheumatoid Arthritis Patients Treated with Abatacept Compared to Those Treated with Tumor Necrosis Factor Inhibitors in Clinical Practice
M. Victoria Hernández¹, Carlos Sánchez-Piedra², Juan D. Cañete¹, Fernando Sanchez-Alonso², Javier Manero³, Ana M. Ortiz Garcia⁴, Eva Pérez-Pampin⁵, Rosa Roselló⁶, Carlos Rodriguez-Lozano⁷, Raimon Sanmarti¹, Juan J. Gómez-Reino⁵ and BIOBADASER 2.0 Study Group, ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ³Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ⁴Rheumatology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ⁵Rheumatology, Hospital Clínico Universitario. Santiago de Compostela, Santiago de Compostela, Spain, ⁶Rheumatology, H San Jorge, Huesca, Spain, ⁷Rheumatology, Hospital de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
Background/Purpose: Currently, the most widely used biological agents for rheumatoid arthritis (RA) patients are the inhibitors of the tumor necrosis factor (TNFi), although other biological…
Abstract Number: 629 • 2016 ACR/ARHP Annual Meeting
Golimumab Improves Patient-Reported Outcomes and Socio- and Health-Economic Parameters in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS): Results from a Non-Interventional Clinical Evaluation in Germany
Klaus Krüger¹, GR Burmester², Siegfried Wassenberg³, Martin Bohl-Buehler⁴ and Matthias H. Thomas⁵, ¹Praxiszentrum St. Bonifatius, München, Germany, ²Charité – University Medicine Berlin, Berlin, Germany, ³Rheumazentrum, Ratingen, Germany, ⁴Friedrich-Ebert-Str. 35, Rheumahaus, Potsdam, Germany, ⁵Medical Affairs, MSD Sharp & Dohme GmbH, Bünde, Germany
Background/Purpose: Golimumab (GLM) has shown its efficacy and safety in various randomized clinical trials with patients eligible for clinical studies. Data from patient-reported outcomes (PROs)…
Abstract Number: 630 • 2016 ACR/ARHP Annual Meeting
Strategies for Biological Drug Quantification in Biological Drug Immune Responses
Michael Kruse Meyer^1,2, Marlene Andersen^1,3, Troels Vindbæk Stausbo⁴, Tue Bjerg Bennike^4,5, Grethe Neumann Andersen^1,6 and Allan Stensballe^3,4, ¹Department of Rheumatology, North Denmark Regional Hospital, Hjørring, Denmark, ²Laboratory for Medical Mass Spectrometry, Aalborg University, Aalborg, Denmark, ³Department of Health Science and Technology, Aalborg University, Aalborg, Denmark, ⁴Laboratory of Medical Mass Spectrometry, Aalborg University, Aalborg, Denmark, ⁵Research Unit for Molecular Diagnostic and Clinical Research, Harvard Medical School, Boston, MA, ⁶Center for Clinical Science, Aalborg University, Hjørring, Denmark
Background/Purpose: The development of the biological DMARDs has benefitted patients, who previously had no treatment options. Currently no method for stratifying patients to these drugs…
Abstract Number: 631 • 2016 ACR/ARHP Annual Meeting
Biologic Free Remission Rate with Etanercept in Rheumatoid Arthritis: A Potential Role of Gender
Alfredomaria Lurati¹, Magda Scarpellini², Katia Angela re³, Mariagrazia Marrazza³, Daniela Mazzocchi³ and Antonella Laria⁴, ¹Fornaroli Hospital Rheumatology Unit Magenta Italy, Magenta, Italy, ²Rheumatology Unit, Ospedale Fornaroli, Magenta, Italy, ³Fornaroli Hospital, Rheumatology Unit, MAgenta, Italy, ⁴Fornaroli Hospital, Rheumatology Unit, Magenta, Italy
Biologic free remission rate with etanercept in rheumatoid arthritis: a potential role of gender A.M. Lurati and A. Laria, D. Mazzocchi, K.A. Re, M. Marrazza,…
Abstract Number: 632 • 2016 ACR/ARHP Annual Meeting
Comparative Improvement in Health-Related Quality of Life for RA Patients Between TNF-α Inhibitors, Other Biologics, and Tofacitinib: Results from a US-Wide Observational Study
Miriam G. Cisternas¹ and Kaleb Michaud^2,3, ¹MGC Data Services, Carlsbad, CA, ²University of Nebraska Medical Center, Omaha, NE, ³National Data Bank for Rheumatic Diseases, Wichita, KS
Background/Purpose: We compared changes from baseline for 8 health-related quality of life (HR-QOL) outcomes over two years for patients with rheumatoid arthritis (RA) treated with…
Abstract Number: 633 • 2016 ACR/ARHP Annual Meeting
High Similarity Between Ex-Vivo Inhibited Cytokine Profiling By Golimumab and Adalimumab As a Putative Explanation for Inferior Treatment Response to Golimumab after Adalimumab Failure in Rheumatoid Arthritis
L. Tweehuysen¹, K. Schraa², M.G. Netea³, F.H.J. van den Hoogen^4,5, L.A.B. Joosten³ and A.A. den Broeder⁴, ¹Sint Maartenskliniek, Nijmegen, Netherlands, ²Internal Medicine, Radboudumc, Nijmegen, Netherlands, ³Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, ⁴Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁵Rheumatology, Radboudumc, Nijmegen, Netherlands
Background/Purpose: Better prediction of treatment response to biologics in rheumatoid arthritis (RA) would contribute to optimal individualized treatment. Clinical data suggest that the response of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].